ArticleOncogene2005
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.British journal of cancer · 2010Pooled it
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.International journal of radiation oncology, biology, physics · 2015Trial
- Stratifying tumor immune microenvironment in head and neck squamous cell carcinoma: from parsing out immune-subtype prognosis to clinically applicable CT-radiomics models.Journal of translational medicine · 2026Article
- Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression.Drugs in context · 2026Review
- Erythropoietin in tissue engineering and beyond: a multifunctional macromolecule with emerging roles in organoids, immune modulation, and cancer research.Frontiers in bioengineering and biotechnology · 2026Review
- Erythropoietin promotes cell proliferation in Neuro-2A mouse neuroblastoma cells.Biochemistry and biophysics reports · 2025Article
- Urothelial collective-gliding response acts as a toll-like receptor 4-associated defense mechanism.iScience · 2025Article
- Efficacy of erythrocyte apheresis in the management of severe high-altitude deacclimatization syndrome: a retrospective cohort study.Frontiers in physiology · 2025Article
- Elucidating the molecular and immune interplay between head and neck squamous cell carcinoma and diffuse large B-cell lymphoma through bioinformatics and machine learning.Translational cancer research · 2024Article
- Integrative methylome and transcriptome analysis reveals epigenetic regulation ofMicrobial genomics · 2024Article
- Targeted therapy for head and neck cancer: signaling pathways and clinical studies.Signal transduction and targeted therapy · 2023Review
- Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology.Journal of experimental & clinical cancer research : CR · 2022Article
- Overexpression of LIMA1 Indicates Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.Clinical Medicine Insights. Oncology · 2022Article
- Identification and validation of neurotrophic factor-related genes signature in HNSCC to predict survival and immune landscapes.Frontiers in genetics · 2022Article
- Review
- STAT5 as a Key Protein of Erythropoietin Signalization.International journal of molecular sciences · 2021Review
- Treatment of anemia in difficult-to-manage patients with chronic kidney disease.Kidney international supplements · 2021Article
- Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.Molecular cancer research : MCR · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. EPO and the EPO receptor (EPOR) are expressed in nonhematopoietic cells and cancers. However, the role of EPO and EPOR within nonhematopoietic cancer cells remains incompletely understood. Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined. In the present study, we demonstrate the previously unrecognized EPO-mediated invasion by HNSCC cells through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens. Pharmacological doses of EPO also had a limited proliferation effect in these cell lines. These results define a novel role for EPO in mediating tumor cell invasion. Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from HNSCC patients further support the role of EPO/EPOR in HNSCC disease progression and metastasis.
Indexed as
Identifiers
15856028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.